HRP20211151T1 - Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama - Google Patents

Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama Download PDF

Info

Publication number
HRP20211151T1
HRP20211151T1 HRP20211151TT HRP20211151T HRP20211151T1 HR P20211151 T1 HRP20211151 T1 HR P20211151T1 HR P20211151T T HRP20211151T T HR P20211151TT HR P20211151 T HRP20211151 T HR P20211151T HR P20211151 T1 HRP20211151 T1 HR P20211151T1
Authority
HR
Croatia
Prior art keywords
disease
cancer
salt
disorder
autoimmune
Prior art date
Application number
HRP20211151TT
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of HRP20211151T1 publication Critical patent/HRP20211151T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (9)

1. Kristalna sol spoja p-toluensulfonske kiseline [image] pri čemu sol pokazuje XRPD uzorak koji ima jedan ili više vrhova odabranih između 5.0, 10.1, 22.1 i 24.5 + 0.2 ° 2Θ, mjereno na X’PertPRO MPD difraktometru opremljenom Cu CFF rendgenskom cijevi; i pri čemu kristalna sol ima raspodjelu veličine čestica d (0.9) od 5 do 50 µm.
2. Sol prema zahtjevu 1, naznačena time, da sol ima d (0.5) od 1 do 10 µm.
3. Sol prema zahtjevu 1 ili zahtjevu 2, naznačena time da sol ima d (0.5) od 2 do 5 µm.
4. Sol prema bilo kojem od zahtjeva 1 do 3, naznačena time, da sol ima d (0.9) od 5 do 25 µm ili 5 do 15 µm.
5. Sol prema bilo kojem od zahtjeva 1 do 4, naznačena time, da sol ima d (0.1) od 0.5 do 1.5 µm ili 0.5 do 1.0 µm.
6. Sol prema bilo kojem od zahtjeva 1 do 5, naznačena time da sol pokazuje uzorak diferencijalnog skenirajućeg kalorimetra (DSC) s karakterističnim endotermnim vrhom na 146 ° C.
7. Farmaceutski pripravak, naznačen time, da sadrži sol prema bilo kojem od prethodnih zahtjeva i farmaceutski prihvatljiv ekscipijens.
8. Farmaceutski pripravak prema zahtjevu 7, naznačen time, da nadalje sadrži jedno ili više dodatnih terapijskih sredstava odabranih između sredstava protiv raka, protuupalnih sredstava, imunosupresiva, steroida, nesteroidnih protuupalnih sredstava, antihistaminika, analgetika i njihovih smjesa.
9. Sol prema bilo kojem od zahtjeva 1 do 6, naznačena time, da se koristi u liječenju bolesti ili poremećaja povezanih s PI3K, naznačena time što je bolest, poremećaj ili stanje povezano s PI3K bolest povezana s imunološkim sustavom, bolest ili poremećaj koji uključuje upalu, rak ili druge proliferativne bolesti, jetrenu bolest ili poremećaj ili bubrežnu bolest ili poremećaj i odabrani su između krvotvornih tumora limfoidne loze, leukemije, akutne limfocitne leukemije, akutne limfoblastne leukemije, B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma, non-Hodgkinsova limfoma, limfoma dlakavih stanica i Burkettova limfoma; hematopoetskih tumora mijeloidne loze, akutne mijelogene leukemije, kronične mijelogene leukemije, mijelodisplastičnog sindroma, mijelocitne leukemije; karcinoma mokraćnog mjehura, karcinoma dojke, karcinoma debelog crijeva, karcinoma bubrega, karcinoma jetre, karcinoma pluća, karcinoma malih stanica pluća, karcinoma jednjaka, karcinoma žuči, raka jajnika, karcinoma gušterače, raka želuca, raka vrata maternice, raka štitnjače, raka prostate, raka kože, karcinoma skvamoznih stanica; tumori mezenhimskog porijekla, fibrosarkoma, rabdomiosarkoma; tumora središnjeg i perifernog živčanog sustava, astrocitoma, neuroblastoma, glioma, svannoma; melanoma, seminoma, teratokarcinoma, osteosarkoma, ksenoderoma pigmentosum, keratoktantoma, folikularni karcinom štitnjače, Kaposijev sarkom, upala, glomerulonefritis, uveitis, jetrene bolesti ili poremećaji, bubrežne bolesti ili poremećaji, kronična opstruktivna plućna bolest, reumatoidni artritis, upalni dermatitis, osteoartritis, upalna bolest mišića, alergijski rinitis, vaginitis, intersticijski cistitis, skleroderma, osteoporoza, ekcem, alogena ili ksenogena transplantacija, odbacivanje transplantata, bolest transplantata protiv domaćina, eritematozni lupus, plućna fibroza, dermatomiozitis, tiroiditis, mijasthezija autoimuna hemolitička anemija, cistična fibroza, kronični recidivirajući hepatitis, primarna bilijarna ciroza, alergijski konjunktivitis, hepatitis, atopijski dermatitis, astma, Sjogrenov sindrom, odbacivanje transplantata organa, multipla skleroza, Guillain-Barre, autoimuni uveitis, autoimuna hemolitička anemija, perniciozna anemija trombocitopenija, temporalni arteritis, antifosfolipidni sindrom, vaskulitidi poput Wegenerove granulomatoze, Behcetove bolesti, psorijaze, dermatitisa herpetiformisa, vulgarnog pemfigusa, vitiliga, Crohnove bolesti, kolitisa, ulceroznog kolitisa, primarne bilijarne imunološke ciroze, autoimunog hepatitisa tipa 1, autoimunog hepatitisa dijabetes melitus, Graveova bolest, Hashimotov tireoiditis, autoimuni ooforitis i orhitis, autoimuni poremećaj nadbubrežne žlijezde, sistemski eritematozni lupus, polimiozitis, dermatomiozitis, ankilozirajući spondilitis, odbacivanje transplantata, odbacivanje transplantata kože, artritis, bolesti kostiju povezane s povećanom resorpcijom kostiju ; ileitis, Barrettov sindrom, respiratorni distres sindrom odrasle osobe, kronična opstruktivna bolest dišnih putova; distrofija rožnice, trahom, onhocercijaza, simpatički oftalmitis, endoftalmitis; gingivitis, parodontitis; tuberkuloza; guba; uremičke komplikacije, nefroza; sklerodermatitis, psorijaza, kronične demijelinizirajuće bolesti živčanog sustava, neurodegeneracija povezana sa AIDS-om, Alzheimerova bolest, zarazni meningitis, encefalomijelitis, Parkinsonova bolest, Huntingtonova bolest, amiotrofična lateralna skleroza virusni ili autoimuni encefalitis; autoimuni poremećaji, vaskulitis imunog kompleksa, sistemski lupus i eritematode; sistemski eritemski lupus (SLE); kardiomiopatija, ishemijska bolest srca hiperkolesterolemija, ateroskleroza, preeklampsija; kronično zatajenje jetre, trauma mozga i leđne moždine i rak.
HRP20211151TT 2014-05-27 2021-07-19 Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama HRP20211151T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2597CH2014 2014-05-27
IN2596CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations
EP15733532.4A EP3149000B1 (en) 2014-05-27 2015-05-26 Crystalline tosylate salt of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
HRP20211151T1 true HRP20211151T1 (hr) 2021-10-15

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211151TT HRP20211151T1 (hr) 2014-05-27 2021-07-19 Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama

Country Status (21)

Country Link
US (4) US9969740B2 (hr)
EP (2) EP3149000B1 (hr)
JP (3) JP6987501B2 (hr)
KR (1) KR20170007480A (hr)
CN (2) CN106661030B (hr)
AU (1) AU2015265542B2 (hr)
BR (1) BR112016027674A2 (hr)
CA (1) CA2949932C (hr)
CY (1) CY1124316T1 (hr)
DK (1) DK3149000T3 (hr)
EA (1) EA032506B1 (hr)
ES (1) ES2880999T3 (hr)
HR (1) HRP20211151T1 (hr)
HU (1) HUE054916T2 (hr)
IL (1) IL249058B2 (hr)
LT (1) LT3149000T (hr)
PL (1) PL3149000T3 (hr)
PT (1) PT3149000T (hr)
RS (1) RS62136B1 (hr)
SI (1) SI3149000T1 (hr)
WO (1) WO2015181728A1 (hr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3149000T1 (sl) * 2014-05-27 2021-09-30 Rhizen Pharmaceuticals S.A. Kristalinična tosilatna sol selektivnega inhibitorja PI3K delta za uporabo v farmacevtskih oblikah
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
BR112019004185A2 (pt) 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
JP2022540466A (ja) 2019-07-15 2022-09-15 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 非晶質ウムブラリシブモノトシレート
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1939203E (pt) * 2000-04-25 2015-02-04 Icos Corp Inibidores da isoforma delta da fosfatidil-inositol 3-quinase humana
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EA201101507A1 (ru) 2009-04-20 2012-05-30 Гилеад Калистога Ллс. Способы лечения солидных опухолей
SI2870157T1 (en) * 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S.A. SELECTIVE PI3K-DELTA INHIBITORS
SI3149000T1 (sl) * 2014-05-27 2021-09-30 Rhizen Pharmaceuticals S.A. Kristalinična tosilatna sol selektivnega inhibitorja PI3K delta za uporabo v farmacevtskih oblikah

Also Published As

Publication number Publication date
US10414773B2 (en) 2019-09-17
CA2949932C (en) 2021-08-10
JP2022082680A (ja) 2022-06-02
BR112016027674A2 (pt) 2017-08-15
CN111635406A (zh) 2020-09-08
SI3149000T1 (sl) 2021-09-30
LT3149000T (lt) 2021-09-10
US20210269446A1 (en) 2021-09-02
EP3149000B1 (en) 2021-06-30
US20190382411A1 (en) 2019-12-19
JP2020122022A (ja) 2020-08-13
EP3149000A1 (en) 2017-04-05
EP3971188A1 (en) 2022-03-23
US10947244B2 (en) 2021-03-16
ES2880999T3 (es) 2021-11-26
US9969740B2 (en) 2018-05-15
HUE054916T2 (hu) 2021-10-28
PT3149000T (pt) 2021-07-27
IL249058A0 (en) 2017-01-31
AU2015265542A1 (en) 2016-12-08
PL3149000T3 (pl) 2021-11-02
WO2015181728A1 (en) 2015-12-03
IL249058B2 (en) 2023-03-01
RS62136B1 (sr) 2021-08-31
CA2949932A1 (en) 2015-12-03
CN106661030B (zh) 2020-06-30
EA032506B1 (ru) 2019-06-28
JP2017516785A (ja) 2017-06-22
US20190016725A1 (en) 2019-01-17
DK3149000T3 (da) 2021-08-30
KR20170007480A (ko) 2017-01-18
US20170121336A1 (en) 2017-05-04
CY1124316T1 (el) 2022-07-22
CN106661030A (zh) 2017-05-10
AU2015265542B2 (en) 2019-05-09
EA201692255A1 (ru) 2017-04-28
JP6987501B2 (ja) 2022-01-05
IL249058B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
HRP20211151T1 (hr) Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama
HRP20171610T1 (hr) Selektivni inhibitori pi3k delta
JP2019163290A5 (hr)
JP2017516785A5 (hr)
JP2017505808A5 (hr)
JP2019519598A5 (hr)
RU2014121073A (ru) Бициклические соединения пиперазина
JP2019515043A5 (hr)
JP2016523973A5 (hr)
JP2020537657A5 (hr)
JP2010509342A5 (hr)
JP2012504605A5 (hr)
HRP20210086T1 (hr) Kristalni metiltioninij-klorid-hidrati
JP2011526244A5 (hr)
HRP20160208T4 (hr) Polimorfi dasatiniba i postupak za njihovu pripremu
JP2017504650A5 (hr)
JP2016537346A5 (hr)
JP2010535218A5 (hr)
JP2013510133A5 (hr)
JP2012504603A5 (hr)
JP2010535215A5 (hr)
RU2007102576A (ru) Новые индаэолкарбоксамиды и их применение
JP2015516968A5 (hr)
JP2018520147A5 (hr)
JP2020506244A5 (hr)